Parade on MSN6d
'I Was Diagnosed With Pulmonary Arterial Hypertension At 25—This Was the First Unexpected Symptom I Experienced'Katrina Berry was 24 years old when she first started experiencing symptoms of pulmonary arterial hypertension (PAH), a ...
Riociguat is generally safe and effective for PAH patients with coexisting cardiac and metabolic conditions, a trials ...
Regarded mostly as a lung disease, PAH is often in people with fewer nail fold capillaries, suggesting a disease of the small ...
GlobalData on MSN1d
Tectonic Therapeutic reports findings from Phase Ia trial of TX45The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.
In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently ...
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...
In The Lancet Respiratory Medicine, Olivier Sitbon and colleagues1 present the results of a randomised, phase 2b clinical trial (ELEVATE-2) that compared the safety and efficacy of pulmonary arterial ...
BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension registry (CTEPH), conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term ...
Researchers identified several inflammatory circulating proteins that could be useful biomarkers for predicting outcomes in ...
Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to ...
The move will enable the country’s more than 100 million chronic pulmonary disease patients to access free annual check-ups.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback